SCHEMBL23770485

SCHEMBL23770485

O=C(O)C1CCCN(c2cccc(SNc3ccc(Cl)c(-c4ccccc4C4CCC4)n3)n2)C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.38
HSD11B1 P28845 1/20 0.36
GPBAR1 Q8TDU6 2/20 0.36
NOTUM Q6P988 3/20 0.35
AKR1C3 P42330 2/20 0.35
AKR1C1 Q04828 1/20 0.35
RORC P51449 4/20 0.34
MPL P40238 1/20 0.34
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34
IDH2 P48735 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PPARG P37231 1/20 0.33
DGAT2 Q96PD7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770668 0.89 GPBAR1 (0.40) P2RX7HSD11B1GPBAR1NOTUMAKR1C3
SCHEMBL23770456 0.88 IDH2 (0.39) HSD11B1NOTUMMPLIDH2DGAT2
SCHEMBL19970141 0.88 IDH2 (0.39) HSD11B1NOTUMMPLIDH2DGAT2
SCHEMBL19970126 0.88 IDH2 (0.39) HSD11B1NOTUMMPLIDH2DGAT2
SCHEMBL23770656 0.88 P2RX7 (0.39) P2RX7HSD11B1GPBAR1NOTUMAKR1C3
SCHEMBL23770813 0.87 ITGB2 (0.40) P2RX7HSD11B1GPBAR1NOTUMAKR1C3
SCHEMBL23770635 0.86 IDH2 (0.39) HSD11B1NOTUMMPLIDH2DGAT2
SCHEMBL23770648 0.84 GPBAR1 (0.41) P2RX7HSD11B1GPBAR1NOTUMIDH2
SCHEMBL23770759 0.83 MPL (0.43) P2RX7GPBAR1NOTUMAKR1C3AKR1C1
SCHEMBL23770690 0.83 DGAT1 (0.33) RORCCCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed